Washington -- The U.S. Food and Drug Administration has approved a new drug, rufinamide -- marketed as Banzel -- to treat severe epilepsy.
The drug is to be used as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome.
"This approval offers another treatment option for patients who suffer from these debilitating, severe seizures," Dr. Russell Katz of the FDA's Center for Drug Evaluation and Research said Thursday in a statement.
Lennox-Gastaut syndrome is a severe form of epilepsy that usually begins before age 4. The FDA said most children with the syndrome experience some degree of impaired intellectual functioning or information processing.
A 4-month clinical trial studying patients ages 4 to 30 found approximately a 41 percent reduction of tonic and atonic seizure frequency and a 20 percent reduction of total seizure frequency.

Recent comments
11 hours 27 min ago
13 hours 24 min ago
14 hours 35 min ago
16 hours 17 min ago
16 hours 52 min ago
1 day 1 hour ago
1 day 2 hours ago
1 day 3 hours ago
1 day 13 hours ago
1 day 14 hours ago